| Gene name: | MIR23A |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | HDF |
| Experiment: | SA-β-gal activity assay//qRT–PCR//Histochemical staining//FACS analysis |
| Description: | Non-senescent fibroblasts were transfected with the miR-23a-3p mimic and oligonucleotide control. Seven days after the transfection, a threefold increase in SA-β-gal was detected.Inhibition of mir-23a-3p in senescent fibroblasts reduced the senescent phenotype of the cells and rescued the loss of the HA matrix. |
| Target gene: | HAS2 |
| Official symbol(s): | HAS2 |
| R-AG-Target gene: | Downregulation |
| Subcategory: | Unclear |
| Target gene experiment: | qRT-PCR//Luciferase reporter assay |
| Target gene description: | Quantitative real-time reverse-transcriptase–PCR (qRT-PCR) analysis revealed that miR-23a-3p expression was increased and HAS2 mRNA expression decreased in senescent compared with non-senescent fibroblasts.In skin biopsies from mice aged 18 and 48 weeks, the miR-23a-3p copy number was increased and the HAS2 mRNA expression decreased, as seen in aged and senescent human dermal fibroblasts previously. Transfection of senescent cells, which display high levels of endogenous miR-23a-3p, with the miR-23a-3p inhibitor increased the HAS2 mRNA copy number twofold. Luciferase activity was not decreased when cells were transfected with luciferase constructs containing a mutated version of the HAS2 3′UTR binding site and the miR-23a-3p mimic . |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...